RRC ID 67922
Author Oshima H, Popivanova BK, Oguma K, Kong D, Ishikawa TO, Oshima M.
Title Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
Journal Cancer Sci
Abstract Cyclooxygenase-2 (COX-2) plays an important role in tumorigenesis through prostaglandin E(2) (PGE(2)) biosynthesis. It has been shown by in vitro studies that PGE(2) signaling transactivates epidermal growth factor receptor (EGFR) through an intracellular mechanism. However, the mechanisms underlying PGE(2)-induced EGFR activation in in vivo tumors are still not fully understood. We previously constructed transgenic mice that develop gastric tumors caused by oncogenic activation and PGE(2) pathway induction. Importantly, expression of EGFR ligands, epiregulin, amphiregulin, heparin-binding EGF-like growth factor, and betacellulin, as well as a disintegrin and metalloproteinases (ADAMs), ADAM8, ADAM9, ADAM10, and ADAM17 were significantly increased in the mouse gastric tumors in a PGE(2) pathway-dependent manner. These ADAMs can activate EGFR by ectodomain shedding of EGFR ligands. Notably, the extensive induction of EGFR ligands and ADAMs was suppressed by inhibition of the PGE(2) receptor EP4. Moreover, EP4 signaling induced expression of amphiregulin and epiregulin in activated macrophages, whereas EP4 pathway was required for basal expression of epiregulin in gastric epithelial cells. In contrast, ADAMs were not induced directly by PGE(2) in these cells, suggesting indirect mechanism possibly through PGE(2)-associated inflammatory responses. These results suggest that PGE(2) signaling through EP4 activates EGFR in gastric tumors through global induction of EGFR ligands and ADAMs in several cell types either by direct or indirect mechanism. Importantly, gastric tumorigenesis of the transgenic mice was significantly suppressed by combination treatment with EGFR and COX-2 inhibitors. Therefore, it is possible that inhibition of both COX-2/PGE(2) and EGFR pathways represents an effective strategy for preventing gastric cancer.
Volume 102(4)
Pages 713-9
Published 2011-4-1
DOI 10.1111/j.1349-7006.2011.01847.x
PMID 21205091
MeSH ADAM Proteins / genetics ADAM Proteins / metabolism Amphiregulin Animals Antigens, CD / genetics Antigens, CD / metabolism Betacellulin Biomarkers, Tumor / genetics Biomarkers, Tumor / metabolism Blotting, Western Cell Proliferation Cells, Cultured Cyclooxygenase 2 / chemistry Cyclooxygenase 2 / metabolism* Cytoskeletal Proteins Dinoprostone / genetics Dinoprostone / metabolism Disease Models, Animal* Disintegrins / genetics Disintegrins / metabolism EGF Family of Proteins Enzyme-Linked Immunosorbent Assay Epidermal Growth Factor / genetics Epidermal Growth Factor / metabolism Epiregulin ErbB Receptors / antagonists & inhibitors ErbB Receptors / genetics ErbB Receptors / metabolism* Gene Expression Profiling Glycoproteins / genetics Glycoproteins / metabolism Immunoenzyme Techniques Immunoprecipitation Intercellular Signaling Peptides and Proteins / genetics Intercellular Signaling Peptides and Proteins / metabolism Macrophages / cytology Macrophages / metabolism Membrane Proteins / genetics Membrane Proteins / metabolism Mice Mice, Transgenic Oligonucleotide Array Sequence Analysis RNA, Messenger / genetics Receptors, Prostaglandin E / genetics Receptors, Prostaglandin E / metabolism* Receptors, Prostaglandin E, EP4 Subtype / genetics Receptors, Prostaglandin E, EP4 Subtype / metabolism* Reverse Transcriptase Polymerase Chain Reaction Signal Transduction Stomach Neoplasms / genetics Stomach Neoplasms / metabolism*
IF 4.966
Human and Animal Cells RAW 264(RCB0535)